Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
Several clinical trials have been reported for ferric derisomaltose where it has been shown
to be well tolerated and to improve markers of IDA. All clinical trials with ferric
derisomaltose have been performed in adults, however, IDA is not specific to the adult
population. In fact, children are likely to develop IDA due to their rapid growth.
The aim in this trial is to evaluate the efficacy and safety of intravenous (IV) ferric
derisomaltose in children 0 to <18 years of age with IDA due to NDD-CKD or with IDA who are
intolerant or unresponsive to oral iron .
The subjects will receive ferric derisomaltose/iron isomaltoside 1000 (Monoferric®/Monofer®),
at single doses of 10 mg/kg or 20 mg/kg with a maximal dose of 1000 mg.
24 subjects will be part of a PK assessment, meaning that more blood samples will be drawn
within the first week after treatment. The blood samples will be used for analysis of the
amount of total iron in the blood from treatment is given to day 7.
For the individual subject, duration of the trial will be approximately 10 weeks (including a
14-day screening period) and each subject will attend 6-9 visits. Subjects who will be
included in the PK assessments will attend 8 (subjects age 6 to <12 years old and 0 to <6
years old) or 9 (subjects age 12 to <18 years old) visits, while the other subjects will
attend 6 visits.